Actively Recruiting
Randomized, Double-Blind Study Comparing EB06 Infusion to Placebo in Adults with Moderate to Severe Non-segmental Vitiligo
Led by Edesa Biotech Inc. · Updated on 2026-10-27
80
Participants Needed
4
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of EB06, a monoclonal antibody, compared with placebo in adults who have moderate to severe non-segmental vitiligo. Vitiligo is a chronic autoimmune skin condition where skin loses pigmentation due to melanocyte destruction. EB06 targets CXCL10, a protein involved in the immune process that damages skin pigment cells, which is linked to the start and persistence of vitiligo patches. Participants receive EB06 through an intravenous infusion starting with a loading dose of 20 mgkg, followed by maintenance doses of 10 mgkg. The study randomly assigns adults to either the EB06 group or a placebo group in a parallel, double-blind design. The main treatment period lasts 28 weeks, during which researchers monitor the impact on skin pigmentation and safety outcomes. During the study, participants undergo regular assessments including skin evaluations using the Facial Vitiligo Area Scoring Index F-VASI at Week 28 as the primary outcome, with additional measures at Weeks 24 and 32. Other evaluations include body surface area affected, patient global impressions, and investigator assessments. Safety and tolerability are also closely monitored throughout the treatment period. The total study duration extends until December 2027, providing a comprehensive view of EB06s effects on vitiligo.
CONDITIONS
Brief Title
A Study of EB06 Versus Placebo in Adults With Moderate to Severe Non-segmental Vitiligo
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here